Exelixis (EXEL) Cash from Restructuring (2013 - 2016)
Exelixis (EXEL) posted quarterly Cash from Restructuring of $130000.0 for Q2 2016, up 143.77% year-over-year from $53328.7 in Q3 2015, and up 112.3% quarter-over-quarter from -$1.1 million in Q1 2016.
Analysis
Exelixis (EXEL) Cash from Restructuring (2013 - 2016) Analysis & Trends
Exelixis' Cash from Restructuring history runs 7 years deep, the most recent figure standing at $130000.0 for Q2 2016.
- In Q2 2016, Cash from Restructuring rose 143.77% year-over-year to $130000.0; the TTM figure through Jun 2016 stood at -$4.8 million (down 82.67% YoY), while the FY2015 annual figure was -$7.2 million, down 211.9% from the prior year.
- Cash from Restructuring for Q2 2016 stood at $130000.0, up from -$1.1 million in the prior quarter.
- The five-year high for Cash from Restructuring was $8.7 million in Q4 2012, with the low at -$3.0 million in Q1 2015.
- The 5-year median for Cash from Restructuring is -$1.1 million (2014), against an average of -$606388.9.
- The sharpest annual moves came in 2014 and 2015: Cash from Restructuring jumped 193.72% in 2014, then sank 908.72% in 2015.
- Exelixis' Cash from Restructuring stood at $8.7 million in 2012, then slumped by 104.92% to -$430000.0 in 2013, then surged by 193.72% to $403000.0 in 2014, then slumped by 459.55% to -$1.4 million in 2015, then jumped by 108.97% to $130000.0 in 2016.
- Business Quant data shows EXEL's Cash from Restructuring at $130000.0 in Q2 2016, -$1.1 million in Q1 2016, and -$1.4 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2016 | 130,000.00 |
| Mar 31, 2016 | -1.06 Mn |
| Dec 31, 2015 | -1.45 Mn |
| Sep 30, 2015 | -2.41 Mn |
| Jun 30, 2015 | -297,000.00 |
| Mar 31, 2015 | -3.02 Mn |
| Dec 31, 2014 | 403,000.00 |
| Sep 30, 2014 | 298,000.00 |
| Jun 30, 2014 | -1.76 Mn |
| Mar 31, 2014 | -1.24 Mn |
| Dec 31, 2013 | -430,000.00 |
| Sep 30, 2013 | -1.97 Mn |
| Jun 30, 2013 | -971,000.00 |
| Mar 31, 2013 | -2.38 Mn |